Consolidated Balance Sheets (June 30, 2013 Unaudited) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 13,245,397	$ 25,652,083
Short-term investments	305,726	2,633,944
Accounts receivable	1,172,444	41,896
Other current assets	730,074	1,078,040
Total current assets	15,453,641	29,405,963
Equipment, net	880,326	986,553
Restricted cash	1,465,214	1,577,920
Other long-term assets	54,033	39,597
Total assets	17,853,214	32,010,033
Current liabilities:
Accounts payable	1,194,219	1,523,875
Accrued expenses	3,021,424	2,410,592
Deferred revenue	2,450,569	3,314,918
Accrued warrant liability	4,757,770	4,105,659
Current portion of capital lease obligation	77,886	71,679
Total current liabilities	11,501,868	11,426,723
Noncurrent portion of capital lease obligation	50,827	97,602
Total liabilities	11,552,695	11,524,325
Stockholders' equity:
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2013 and December 31, 2012, respectively
Common stock, $.005 par value; 160,000,000 shares authorized, 44,970,989 shares issued and outstanding as of June 30, 2013; 80,000,000 shares authorized, 44,730,445 shares issued and outstanding as of December 31, 2012	224,855	223,653
Additional paid-in capital	124,792,077	123,864,830
Accumulated other comprehensive income	288,467	546,473
Accumulated deficit	(131,108,223)	(118,301,789)
Total Cleveland BioLabs, Inc. stockholders' (deficit) equity	(5,802,824)	6,333,167
Noncontrolling interest in stockholders' equity	12,103,343	14,152,541
Total stockholders' equity	6,300,519	20,485,708
Total liabilities and stockholders' equity	$ 17,853,214	$ 32,010,033